Lisinopril (dihydrate)

83915-83-7

C21H35N3O7

DMSO : < 1 mg/mL (insoluble or slightly soluble); H2O : 20 mg/mL (45.30 mM; Need ultrasonic)

Metabolic Enzyme/Protease

Lisinopri (dihydrate) (lMK-521 (dihydrate)) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks. . IC50 & Target: ACE. In Vitro: Lisinopri (dihydrate) (lMK-521 (dihydrate)) is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy^[1][2].